Marques M B
Centro de Informacao Cientifica e Technologica de Fundacao Oswaldo Cruz, Brasil.
Hist Cienc Saude Manguinhos. 2000 Mar-Jun;7(1):7-21.
Passage of Patent Law 9279/96, in effect since April 1997, has made relations between pharmaceutical patents and accessibility to medicine in Brazil complex. Under the new law, patents may extend to chemical inventions (products and process) and transgenic microorganisms. The issue is analyzed from two specific yet inter-related approaches: science and technology policy and health-care policy. The conclusion draws attention to the main future consequences of current international trends, both legal and regulatory. Brazil should ready its legal framework to respond to the negative consequences that genome patenting can be expected to have on the flow of scientific information and on access to pharmaceutical drugs.
自1997年4月起生效的第9279/96号《专利法》使巴西的药品专利与药品可及性之间的关系变得复杂。根据新法律，专利可涵盖化学发明（产品和方法）以及转基因微生物。本文从两个具体但相互关联的角度对该问题进行了分析：科技政策和医疗保健政策。结论部分提请注意当前国际趋势（包括法律和监管方面）未来可能产生的主要后果。巴西应完善其法律框架，以应对基因专利预计会对科学信息流通和药品获取产生的负面影响。
